BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SEEK Announces Publication of HIV-v Data in Vaccine Journal


11/1/2013 10:03:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

London, UK, 01 November 2013: SEEK, a privately-owned UK pharmaceutical group, announces today that results from its HIV Phase Ib immunotherapy trial have been published in the peer-reviewed medical journal Vaccine.

Commenting on the announcement, Gregory Stoloff, CEO of SEEK Group said: “We are very pleased that Vaccine has published the results on the HIV-v immunotherapy Phase Ib trial. These data show that HIV-v has potential as an immunotherapeutic anti-viral agent in treating HIV. We are very pleased to see that other researchers, such as Harvard1 and National Institute of Allergy and Infectious Diseases2, are also pursuing the approach of creating antibodies to target conserved regions of the virus.”

SEEK’s HIV immunotherapy triggers the immune system’s cellular and antibody responses to selectively identify and kill HIV infected cells. The most exciting aspect of this therapy is that it directs the immune system towards short, highly conserved regions of proteins produced by most circulating HIV strains. The triggered immune responses are highly effective both independently and in combination.

The immunotherapy offers an advantage over anti-retroviral medicines; it not only slows down the viral replication but also causes the cells that house the virus to be destroyed. This implies that the immunotherapy should be able to deal with the latency of the virus, an area of focus and interest to date. The antibodies from the HIV immunotherapy target and bind to conserved regions of HIV proteins that are presented on the cell surface of HIV infected cells. Macrophages and T cells then destroy the cells housing the virus which eliminates the latent viruses within that cell.

Research from Harvard Medical School and the National Institute of Allergy and Infectious Diseases showed that an antibody to conserved regions of the virus was effective in reducing viral load in rhesus macaques. SEEK’s study showed it is effective in humans as well.

Since this antibody targets a conserved HIV protein expressed on the surface of infected tissue rather than on the virus itself, it is able to eliminate the virus in infected tissue and eliminate the latent virus.

1 Harvard Medical School, US. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013)

2 National Institute of Allergy and Infectious Diseases, US. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013)

SEEK is in discussions with potential partners to collaborate with on the immunotherapy. The publication, “Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial”, Vaccine Volume 31, Issue 48, 19 November 2013, can be found at the following URL: http://www.sciencedirect.com/science/article/pii/S0264410X13013273

For more information please contact:

Gregory Stoloff, CEO, SEEK Tel +44 (0)20 7153 6570

Hume Brophy

Mary Clark / Hollie Vile / Supriya Mathur Tel +44 (0)20 3440 5654

seek@humebrophy.com

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low cost medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.

Additional information about SEEK is available on the Company’s website located at www.seekacure.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES